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MRI-derived features of presumed cerebral small vessel disease are frequently found in Alzheimer’s disease. Influences of such
markers on disease-progression measures are poorly understood. We measured markers of presumed small vessel disease (white
matter hyperintensity volumes; cerebral microbleeds) on baseline images of newly enrolled individuals in the Alzheimer’s Disease
Neuroimaging Initiative cohort (GO and 2) and used linear mixed models to relate these to subsequent atrophy and neuropsycho-
logical score change. We also assessed heterogeneity in white matter hyperintensity positioning within biomarker abnormality
sequences, driven by the data, using the Subtype and Stage Inference algorithm. This study recruited both sexes and included: con-
trols: [n¼ 159, mean(SD) age¼74(6) years]; early and late mild cognitive impairment [ns¼ 265 and 139, respectively, mean(SD)
ages ¼71(7) and 72(8) years, respectively]; Alzheimer’s disease [n¼103, mean(SD) age¼ 75(8)] and significant memory concern
[n¼72, mean(SD) age¼ 72(6) years]. Baseline demographic and vascular risk-factor data, and longitudinal cognitive scores (Mini-
Mental State Examination; logical memory; and Trails A and B) were collected. Whole-brain and hippocampal volume change
metrics were calculated. White matter hyperintensity volumes were associated with greater whole-brain and hippocampal volume
changes independently of cerebral microbleeds (a doubling of baseline white matter hyperintensity was associated with an increase
in atrophy rate of 0.3 ml/year for brain and 0.013 ml/year for hippocampus). Cerebral microbleeds were found in 15% of individu-
als and the presence of a microbleed, as opposed to none, was associated with increases in atrophy rate of 1.4 ml/year for whole
brain and 0.021 ml/year for hippocampus. White matter hyperintensities were predictive of greater decline in all neuropsychologic-
al scores, while cerebral microbleeds were predictive of decline in logical memory (immediate recall) and Mini-Mental State
Examination scores. We identified distinct groups with specific sequences of biomarker abnormality using continuous baseline
measures and brain volume change. Four clusters were found; Group 1 showed early Alzheimer’s pathology; Group 2 showed early
neurodegeneration; Group 3 had early mixed Alzheimer’s and cerebrovascular pathology; Group 4 had early neuropsychological
score abnormalities. White matter hyperintensity volumes becoming abnormal was a late event for Groups 1 and 4 and an early
event for 2 and 3. In summary, white matter hyperintensities and microbleeds were independently associated with progressive neu-
rodegeneration (brain atrophy rates) and cognitive decline (change in neuropsychological scores). Mechanisms involving white mat-
ter hyperintensities and progression and microbleeds and progression may be partially separate. Distinct sequences of biomarker
progression were found. White matter hyperintensity development was an early event in two sequences.
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Introduction
White matter hyperintensities (WMHs), lacunes and cerebral
microbleeds (CMBs) are features of presumed cerebral small
vessel disease (SVD) which increase with age and are often
found in Alzheimer’s disease.1–4 Different SVD markers like-
ly reflect different disease processes and vascular pathologies
and may independently contribute to neurodegeneration
and cognitive decline. This study investigates whether SVD
markers are associated with Alzheimer’s disease progression
measures in a cohort including normal ageing and all puta-
tive stages of Alzheimer’s disease. The study also assesses
whether SVD is an early marker of disease relative to clas-
sical Alzheimer’s disease measures. Together, this allows for
a better understanding of the presumed vascular contribu-
tions to Alzheimer’s disease.
Disease progression is often assessed using measures of
cognitive decline and neurodegeneration. Cognitive de-
cline is measured using changes in neuropsychological
scores, whereas a commonly used proxy of neurodegener-
ation is brain atrophy rates measured using serial MRI.5
WMHs are associated with higher atrophy rates in nor-
mal ageing and mild cognitive impairment (MCI).6–8
Contrastingly, the association of CMBs with atrophy
rates is poorly understood; one study found no associ-
ation between brain volume change prior to CMB
development.9
Data-driven techniques give insight into another feature
of progression: the sequence in which biomarkers become
abnormal.10 These techniques can provide information
regarding the heterogeneity and uncertainty of different
biomarker progression sequences and possible sub-group
aetiologies. This information is crucial in understanding
whether multiple disease-progression models, which in-
clude presumed vascular markers, are needed.
This study investigated SVD markers in a cohort
including normally ageing individuals, those with signifi-
cant memory concern (SMC), early and late cognitive im-
pairment (EMCI and LMCI) and clinical Alzheimer’s
disease. We assessed independent relationships of baseline
WMHs and CMBs with: (i) brain and hippocampal atro-
phy rates using the boundary shift integral (BSI); and
(ii) changes in neuropsychological scores. We also per-
formed analyses to determine clusters of individuals that
follow different temporal sequences of biomarkers becom-
ing abnormal. We hypothesized that SVD measures
would independently and partially predict progression
measures, and that a data-driven approach would reveal
heterogeneity in biomarker progression sequences.
Methods
Subjects
Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database (adni.loni.usc.edu). ADNI was launched
in 2003 as a public–private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary goal
of ADNI has been to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression
of MCI and early Alzheimer’s disease. For up-to-date in-
formation, see www.adni-info.org Accessed 07 October
2021. Newly enrolled clinically defined participants from
ADNI2 and ADNIGo (ADNI2/GO) were analysed in this
study. This included controls, SMC, EMCI, LMCI and
Alzheimer’s disease. SMC were included since they are at
higher risk of decline and may be different to controls
without memory concerns.
Inclusion criteria for all individuals were that they were
good general health, were between 55 and 90 (inclusive)
years of age, had a reliable study partner, could speak
English or Spanish, and had Hachinski score < 5.11
Controls, SMC, EMCI and LMCI had to have Mini-
Mental State Examination (MMSE) scores were between
24 and 30 (inclusive). Controls and SMC had to have a
clinical dementia rating (CDR) of 0, both MCI groups
had to have a CDR of 0.5. Controls, SMC, EMCI and
LMCI had to have preserved activities of daily living and
an absence of dementia. SMC, EMCI, LMCI and
Alzheimer’s disease had to have subjective memory con-
cerns. Controls and SMC had to be normally functioning
as measured by education-adjusted scores on delayed re-
call of one paragraph from Wechsler Memory Scale
Logical Memory II.
Specific inclusion criteria were in place for all groups.
Controls had to have no memory complaints. SMC had
to have a cognitive change index score of more than 15.
EMCI subjects were separated from LMCI subjects on
the Wechsler Memory Scale Logical Memory II. EMCI
had to have scores for 16 years of education: 9–11; for
8–15 years of education: 5–9; or for 0–7 years of educa-
tion: 3–6. LMCI had to have scores for 16 years of
education of 8; for 8–15 years of education: 4; for
0–7 years of education: 2. Alzheimer’s disease partici-
pants had MMSE between 20 and 26 inclusive, a CDR
of 0.5 or 1.0 and had to meet NINCDS/ADRDA criteria
for probable Alzheimer’s disease.
For inclusion in this study, individuals required good
quality serial T1-weighted MRI necessary for atrophy rate
measurement, a good quality SPM12 (https://www.fil.ion.
ucl.ac.uk/spm/ Accessed 07 October 2021) segmentation
to generate total intracranial volume (TIV) as well as a
good quality baseline WMH measurement.
Imaging
All images were from 3 T scanners and underwent stand-
ard quality control at the Mayo Clinic (Rochester, MN,
USA), which included protocol compliance check, inspec-
tion for clinically significant structural abnormalities, and
image quality assessment. This study utilized unprocessed
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baseline non-accelerated T1-weighted MRI and baseline
FLAIR and T2* images (for SVD measurement). For esti-
mation of atrophy rates serial accelerated T1-weighted
MRI imaging12 was used which had preprocessing per-
formed at Mayo including correction of gradient warp-
ing13 and reduction of image inhomogeneity.14 Individual
accelerated T1-weighted images were additionally checked
at the Dementia Research Centre (DRC), UCL, London,
UK, for significant motion artefacts that would cause
blurring at tissue boundaries. T1-weighted images were
near-isotropic, FLAIR images had a slice thickness of
5 mm, and T2* of 4 mm (see http://adni.loni.usc.edu/meth
ods/documents/mri-protocols/ Accessed 07 October 2021).
For atrophy rate estimation, only images obtained using
the same scanner as the baseline assessment were used.
SVD marker detection
SVD measurement examples are shown in Fig. 1.
Supratentorial white matter and deep grey matter hyper-
intensities (WMH) were estimated on FLAIR images, in
combination with the T1-weighted image, using BaMoS.
15
This automated technique segments WMHs by modelling
each tissue class (grey, white, CSF and non-brain) as a
mixture of Gaussians whose number is automatically and
dynamically determined using a split-and-merge strategy
and constrained by anatomical probabilistic atlases and
neighbourhood constraints (using Markov Random
Fields). Both a skull-stripping mask and subject-specific
statistical tissue priors were obtained as a result of the
label-fusion GIF framework.16 After convergence of the
models, candidate lesion voxels from the outlier compo-
nents of the data model were selected based on their lo-
cation and intensity compared with healthy-appearing
white matter. Connected components of these voxels
were then automatically classified as lesion or artefact
based on anatomical and shape rules. The final WMH
volume is obtained from the integration of the probability
maps of selected lesions, with the probabilities defined
based on the level of outlierness compared with healthy
white matter. All WMH binary masks were inspected by
an experienced rater.
For CMB labelling, FLAIR and T1-weighted images
were linearly registered to the T2* space using NiftyReg
17
to ensure that the lower-resolution T2* remained in na-
tive space. CMBs were identified on T2* images with co-
registered FLAIR and T1-weighted images available for
reference using the open-source viewer NiftyMidas.18
Figure 1 Small vessel disease markers. Axial views of A white matter hyperintensity (outlined in red) on a FLAIR image; B Cerebral
microbleeds unlabelled with labelling shown underneath (yellow crosses) on a T2* image; C a lacune with labelling shown underneath (yellow
cross) on a FLAIR image.
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During identification, CMBs were counted and marked
(see Fig. 1). To be considered a CMB, the hypointensity
on T2* had to be small, <10 mm in diameter, well-
defined, and either ovoid or round. The CMB had to be
blooming on the T2* compared with the other imaging
sequences. CMB mimics, including vessels, mineralization,
partial volume and air-bone interface artefacts,19 were
identified using all imaging types, and disregarded. Care
was taken to ensure the same CMB was not counted on
multiple slices. One rater marked all CMBs, with the
manual counts performed according to the MARS scale.19
Hypointensities on T2* that were difficult to confirm as
CMBs were checked with a neuroradiologist.
Lacunes of presumed vascular origin4 were identified
on FLAIR images in a similar manner to CMBs. Co-reg-
istered T1-weighted to FLAIR images were used to aid
lacune identification in a similar process to CMBs. A
lacune was recorded and marked using NiftyMidas (see
Fig. 1) if a hypointense area on the FLAIR images corre-
sponded to a region of hypointensity on the registered
T1-weighted images with CSF-like signal on both. These
often had a hyperintense rim on FLAIR. Lacunes were
only included in the regions of white matter in the terri-
tory of perforating arterioles: specifically those from the
posterior cerebral artery and the middle cerebral artery.
The size of the lacune was important4; there was a lower
limit of 3 mm and an upper limit of 15 mm in diam-
eter as inclusion criteria. All lacunes were checked by a
neuroradiologist.
Whole-brain segmentations were generated using Brain
MAPS20 and hippocampal regions using STEPS.21
Regions were checked and edited where necessary by
experienced raters at the DRC. Symmetric whole-brain
and hippocampi BSIs were calculated following registra-
tion into a within-subject group-wise space.22 Changes in
volume from baseline were used in analyses. TIV was cal-
culated using a published method which sums the tissue




MMSE, Trails A and B, and logical memory—immediate
recall (LIMM) were downloaded. These tests cover gen-
eral cognition with a memory bias (MMSE), processing
speed (Trails A), executive function (Trails B) and logical
memory (LIMM). Baseline age, APOE e4 status, history
of hypertension and smoking, height and weight, diabetes
status, years in education, gender and CSF amyloid beta
(Ab 1–42), total tau (tau) and phosphorylated (ptau)
were downloaded. CSF measures were those from the
micro-bead-based multiplex immunoassay, the INNO-BIA
AlzBio3 RUO test (Fujirebio, Ghent, Belgium) on the
Luminex platform. Baseline geriatric depression scale total
scores and change in diagnosis identifications for the 12-
month time-point were downloaded.
Statistical analysis
Variables of interest
Outcomes of interest modelled separately were (i) neuro-
degeneration measures: brain and hippocampal atrophy
rates; and (ii) cognitive decline measures: changes in
LIMM, MMSE, Trails A and Trails B. Predictors of
interest were baseline: WMH volumes and presence of
CMBs. These predictors were used both in separate mod-
els, and, also together to assess independence of predic-
tion of outcomes.
Variable transformation
WMHs were log2 transformed, owing to skewness. Body
mass index (BMI) was calculated from height and weight
variables (kg/m2). CMBs were treated as binary variables,
indicating the presence of at least one CMB. For CMBs,
the count data were not normally distributed with the
majority of individuals having either no CMBs or a single
CMB and therefore we chose to investigate CMB as a
binary variable. The inverse of Trails A and Trails B was
used in the linear mixed-effects models described below
to improve model fit.
Analysis of baseline demographic,
neuropsychological and imaging variables
STATA v13 or later was used for all statistical tests. All
tests were two-tailed and the alpha-level used was
P< 0.05. P-values in this first set of analyses represent
differences between diagnostic groups. Fisher’s exact test
was used to assess differences in distribution of gender
and APOEe4 carrier (binary) status, presence of lacunes
and CMB, diabetes status, and history of hypertension
across diagnostic groups. Differences according to smok-
ing and race were examined using chi2 tests. For all other
variables, linear regression was used to compare the diag-
nostic groups at baseline adjusting for relevant confound-
ers by including them as additional predictors in the
model. Comparison of log2WMH was adjusted for TIV
and comparison of brain volume, and hippocampal vol-
ume was adjusted for age, gender and TIV as these have
been found to be confounders in cross-sectional analy-
ses.24 Comparison of neuropsychological scores was
adjusted for age, gender and education as these are
known cross-sectional confounders.25
Atrophy rates with SVD predictors
For brain and hippocampal volume change, linear mixed-
effects models for directly measured change were fitted
on the whole dataset.26 Brain or hippocampal atrophy
rate, was the outcome, with WMH or CMB variables as
predictors. Atrophy was measured using available T1-
weighted MRI, from screening to 3-, 6-, 12-, 24-month
interval scans, then annual assessments beyond 24-
months for all groups except the Alzheimer’s disease
group. The mixed-effects models allow for missing atro-
phy rate measures. Interactions between WMH or CMB
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markers and time were used to estimate associations be-
tween SVD and rate of atrophy (the outcome of interest).
Separate models for each type of atrophy were fitted, as
well as for WMH or CMBs as predictors. The effects of
lacunes were not reported owing to low prevalence.
Models for each outcome including all three markers of
SVD were also fitted. All models were adjusted for TIV
and diagnostic group. To account for repeated measures,
random slopes and intercepts at the level of the individ-
ual were included. A different random slope and intercept
variance was estimated for each diagnostic group, to
allow for different levels of variation in atrophy and at-
rophy rate between groups. We further fitted interactions
between WMH or CMB, time and diagnostic group to
test for the differential effect of either WMH or CMB
measurements on atrophy rates between diagnostic
groups. We fitted another pair of models including both
CMB and WMH allowing an interaction between the
main effects of CMB and WMH and the effect of CMB
and WMH on the rate of change in the outcomes to as-
sess for a multiplicative effect of the presence of CMBs
on the effect of WMH on the outcome of interest.
Psychology test modelling with SVD predictors
Linear mixed-effects models were used to assess whether
the WMH and CMB markers predicted changes in neuro-
psychological scores. Scores were the outcome, with WMH
and CMB variables as predictors. Scores were used from
screening or baseline, 6-, 12-month intervals then annual
assessments for all tests apart from LIMM which was not
assessed at 6-months. Individuals with Alzheimer’s disease
were not followed beyond 24 months. The mixed-effects
models allow for missing neuropsychological scores.
Interactions between WMH and CMB markers and time
were used to estimate associations between these SVD
markers and neuropsychological score change (the outcome
of interest). Separate models for each score were fitted, as
well as for WMH and CMB separately. Models for each
outcome including all three markers of SVD were also fit-
ted. All models included random slopes and intercepts at
the level of the individual. Different random effect variances
were estimated for control, Alzheimer’s disease and pooled
MCI and SMC groups. Correlations between intercepts and
slopes were permitted by using unstructured covariance
matrices within each group. Where models did not converge
the random effects structure was simplified by combining
the control, MCI and SMC groups (see Supplementary
methods). For MMSE, inference was based on bias-cor-
rected and accelerated bootstrap confidence intervals from
2000 replications since it was not possible to transform
MMSE to allow the residuals to follow a normal distribu-
tion. We fitted further models to assess evidence for the dif-
ferential effect of WMH and CMBs on score change
between diagnostic groups. These models included as pre-
dictors: WMH or CMB; interaction between WMH or
CMB measure and diagnostic group; and a three-way inter-
action between the WMH or CMB, diagnostic group and
time. We fitted another set of models including both CMB
and WMH allowing an interaction between the main effects
of CMB and WMH and the effect of CMB and WMH on
the slopes of the outcomes to assess whether there was a
multiplicative effect of CMB presence on the effect of
WMH on neuropsychological scores.
Disease-progression measurement modelling
Individuals with complete data for all baseline measures
of interest and baseline to 12-month atrophy rate and
neuropsychological tests were used. The Subtype and
Stage Inference (SuStaIn) algorithm27 was used to deter-
mine groups of individuals with distinct progression
sequences. Progression sequences are orderings of bio-
markers becoming abnormal, i.e. an event-based model
(EBM).10,28 An important feature of this approach is that
the sequence of events is estimated from the data, rather
than relying on a priori clinical staging. Furthermore, the
uncertainty of sequences can be ascertained. The occur-
rence of each event is informed by a probability measure,
estimated by fitting a mixture of two Gaussians to each
biomarker to determine the likelihood a biomarker meas-
urement is ‘normal’ or ‘abnormal’. The SuStaIn algorithm
is then used to simultaneously cluster individuals into
groups, estimate an event sequence for each group, and
derive a biomarker severity stage (SuStaIn stage) for each
subject. The uncertainty in the sequence of the events for
each cluster is then determined using a Markov Chain
Monte Carlo (MCMC) algorithm. This produces a single
most likely sequence as well as a relative likelihood of
other sequences enabling assessment of uncertainty.28
Only single continuous measurements for a variable of
interest can be used in this approach, such as baseline
measures and change metrics (difference between two
time-points). CSFAb1–42, tau and ptau, whole-brain BSI,
hippocampal BSI, log2WMH and first assessment MMSE,
Trails A, Trails B and LIMM were used. Measures such
as presence of CMBs, and changes in neuropsychology
scores were not included due to the binary nature of the
CMBs and variance in neuropsychological score change.
Between-cluster differences were then assessed for varia-
bles of interest not included in the models. We assessed
differences in the initial diagnostic group, SuStaIn stage,
baseline age, gender, years of education, hypertension,
smoking history, BMI, APOE e4 carrier status, presence
of CMBs, brain volume, hippocampal volume, geriatric
depression score, and annualized changes calculated from
the baseline and 12-month values of MMSE, Trails A,
Trials B, LIMM. The tests used included chi2 for diag-
nostic group at baseline, SuStaIn stage and smoking sta-
tus. For gender, history of hypertension, APOE e4 status,
presence of microbleeds and diabetes status, Fisher’s exact
test was used. For age, education, BMI, neuropsycho-
logical change scores, brain volumes, hippocampal vol-
umes and geriatric depression scale total scores, linear
regression was used. TIV, age and gender were used to
adjust the analysis of brain and hippocampal volumes
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across clusters. Gender was used to adjust the analysis of
years in education. We also report the percentage of indi-
viduals who change diagnostic group between baseline
and the 12-month time-point.
To aid interpretability we also report mean (SD) varia-
bles entered into SuStaIn EBM by subtype (derived
group) without statistical testing across grouping.
Data availability
ADNI data are available for download for approved
researchers (www.adni-info.org Accessed 07 October 2021).
The NiftyMidas visualization and labelling software is avail-
able (https://github.com/NifTK/NifTK Accessed 07 October





Seven hundred and thirty-eight subjects with good-quality
WMHs, TIVs and brain atrophy rate measurements were
included in the main analysis, see Fig. 2. A subset of
those with WMH segmentations had complete lacune
(n¼ 731) and CMB data (n¼ 717). For hippocampi, a
subset of individuals with hippocampal volumes changes
were available with WMH data (n¼ 717), lacune data
(n¼ 710) and CMB data (n¼ 697).
Demographics
Participant groups differed in age, with the EMCI as the
youngest (71.4 years) and Alzheimer’s disease (75.0 years)
as the oldest group (see Table 1). The Alzheimer’s disease
group also had the highest frequency of APOE e4 car-
riers, the lowest level of education and the lowest BMI.
There was no evidence of any differences in race, dia-
betes or gender proportions between groups.
Imaging measures at baseline
Alzheimer’s disease participants had, on average, signifi-
cantly greater WMH volume than other groups. There
was a low prevalence of lacunes (2% overall) and preva-
lence of CMBs was 15%. There were no significant dif-
ferences in proportions of subjects with a CMB or lacune
across subject groups. Brain and hippocampal volumes
differed across groups with volumes in the Alzheimer’s
disease group being the smallest.
Atrophy rates
Atrophy rates across the diagnostic groups
All groups experienced significant brain and hippocampal
volume loss over time (see Table 2). The fully adjusted
model indicated that controls experienced brain atrophy at
an average rate of 5.3 ml/year and hippocampal atrophy at
0.04 ml/year, for average TIV and log2WMH, and with no
lacunes, and CMBs. Atrophy rates in SMC were not signifi-
cantly different from controls. Atrophy rates were signifi-
cantly higher in EMCI patients than controls, with an
average whole-brain atrophy rate of 6.8 ml/year, and a hip-
pocampal atrophy rate of 0.06 ml/year. LMCI patients also
had a greater mean adjusted atrophy rates than controls, at
9.3 ml/year for the whole brain and 0.11 ml/year for the
hippocampus. Individuals with Alzheimer’s disease had the
highest mean-adjusted whole-brain atrophy rate (14.7 ml/
year) and hippocampal atrophy rates (0.19 ml/year).
SVD predicting atrophy rates
WMHs and CMBs separately and independently pre-
dicted hippocampal and whole-brain atrophy rate across
all individuals adjusted for diagnostic group (see
Table 2). For both of these predictors, an increase in
WMH or presence of CMB was associated with greater
volume loss. A doubling of baseline WMH volume was
associated with an increase in whole-brain atrophy rates
Figure 2 Flowchart depicting subject selection for analysis.
Definitions: white matter hyperintensity (WMH); statistical
parametric mapping (SPM); total intracranial volume (TIV).
Small vessel disease and Alzheimer’s BRAIN COMMUNICATIONS 2021: Page 7 of 15 | 7
of 0.3 ml/year (95% CI 0.1, 0.6) and an increase in hip-
pocampal atrophy of 0.013 ml/year (95% CI 0.009,
0.017). Presence of a least one CMB, compared with
those without CMB, was associated with an increase in
1.5 ml/year (95% CI 0.5, 2.5) whole-brain atrophy and
an increase in hippocampal atrophy of 0.029 ml/year
(95% CI 0.013, 0.045). There was no evidence that the
association of WMH with atrophy rate differed according
to diagnostic group (P¼ 0.62 for whole-brain and
P¼ 0.70 for hippocampal atrophy rate) or that the asso-
ciation of CMBs differed by diagnostic group (P¼ 0.12
for whole brain and P¼ 0.18 for hippocampal atrophy).
There was no evidence to suggest the association between
WMH and atrophy rates differed in those with and with-
out a CMB for either the whole brain (P¼ 0.14) or the
hippocampus (P¼ 0.38) over all participants.
Neuropsychology
Neuropsychological changes across the diagnostic
groups
Table 3 shows the change in neuropsychology results
and the associations between SVD measures and these
changes. Controls saw either no evidence of change in
neuropsychology measures over time (MMSE, Trails A
and B) or a modest improvement over time [LIMM,
Table 1 Subject demographics and basic imaging information for the ADNI2/Go cohort





N 159 72 265 139 103
Age at baseline, years 73.7 (6.2) 72.0 (5.6) 71.4 (7.3) 71.9 (7.7) 75.0 (7.8) <0.001
Male (%) 46.5 44.4 54.3 54.0 59.2 0.2
Hypertension (% hypertensive) 51.6 41.7 50.9 44.6 45.6 0.4
Smoking (% never/historical/
current)
60.4/35.9/3.8 52.8/44.4/2.8 60.4/38.1/1.5 67.6/30.2/2.2 64.1/32.0/3.9 0.4
Body mass index, kg/m2 27.2 (4.3)b 28.0 (6.4)a 28.0 (5.3) 27.4 (5.0) 25.6 (4.2) 0.001
Percentage with diabetes 6.9 12.5 11.3 8.6 8.8a 0.5
Percentage APOE e4 carriers 28.9 37.5 42.3 56.8 73.8 <0.001
Years of education 16.5 (2.5) 17.0 (2.4) 16.0 (2.7) 16.7 (2.5) 15.7 (2.7) <0.001
First assessment MMSE 29.0 (1.3) 29.0 (1.2) 28.3 (1.6) 27.6 (1.9) 23.1 (2.1) Not appropriate
First assessment Trails A 33.6 (10.5) 34.7 (12.7) 36.0 (12.7) 41.7 (17.5) 60.7 (33.7)a <0.001
First assessment Trails B 82.7 (44.4)a 87.0 (46.9) 95.9 (45.7)d 115.7 (63.2)c 193.2 (86.5)h <0.001
First assessment LIMM 14.3 (2.9) 14.3 (3.3) 11.0 (2.7) 7.1 (3.0) 4.0 (2.6) <0.001
Race (%)
Asian 1.26 0.00 1.51 0.72 2.91
Native Hawaiian or Pacific 0.00 0.00 0.38 0.72 0.00
Black or African American 8.81 1.39 1.51 2.88 2.91
American Indian or Alaskan 0.00 0.00 0.38 0.00 0.00 0.2
White 88.68 95.83 93.96 94.96 93.20
More than one race 1.26 2.78 1.51 0.72 0.97
Race unknown 0.00 0.00 0.75 0.00 0.00
MRI follow-up time from baseline
for whole brain atrophy rates
(years)
2.4 (1.3) 1.7 (0.8) 2.4 (1.3) 2.2 (1.3) 1.0 (0.5) Not appropriate
Number of MRI visits for whole
brain atrophy
4.7 (1.2) 2.8 (0.9) 4.4 (1.2) 4.5 (1.0) 3.4 (1.0) Not appropriate
Baseline WMH (ml) 3.5 (4.9) 3.6 (4.1) 3.9 (6.9) 3.6 (6.3) 6.1 (8.9) 0.01
Lacunes n (%) 3 (1.9)b 1 (1.4)a 11 (4.2)b 0 (0.0)a 2 (2.0)a 0.1
CMB (1 or more) n (%) 27 (17.8)f 6 (8.6)b 36 (14.0)g 17 (12.4)b 21 (20.8)b 0.2
Whole-brain volume, ml 1068 (105) 1094 (88) 1083 (108) 1067 (101) 1027 (117) <0.001
Total (left plus right) hippocampal
volume, ml
5.46 (0.65) 5.68 (0.70)a 5.43 (0.73)e 5.09 (0.83) 4.60 (0.71) <0.001
Demographics are shown for controls, Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI), Subjective Memory Concern (SMC) and Alzheimer’s dis-
ease. Values are mean (SD) unless stated in the table, White matter hyperintensity (WMH) is reported as median (interquartile range). P-values represent the result of a single test
over all groups.
LIMM, logical memory immediate recall score; MMSE, Mini-Mental State Examination.
aMissing in 1 subject.
bMissing in 2 subjects.
cMissing in 3 subjects.
dMissing in 4 subjects.
eMissing in 5 subjects.
fMissing in 7 subjects.
gMissing in 8 subjects.
hMissing in 12 subjects.
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0.23; (95% CI 0.09, 0.37) points/year]. SMC saw no
significant changes over time. EMCI only showed sig-
nificant decline in MMSE over time 0.21 (95% CI
0.32, 0.12). LMCI and Alzheimer’s disease tended
to show decline on all measures, but decline was statis-
tically significant only for the LMCI group for MMSE
and Trails B and for Alzheimer’s disease for MMSE
and Trails A. For MMSE, this was a decline of 1.01
points per year for LMCI (95% CI 1.30, 0.78) and
2.34 points per year for Alzheimer’s disease (95% CI
3.13, 1.74). Significant differences were seen be-
tween controls and EMCI for MMSE, LMCI for
LIMM and MMSE and between controls and
Alzheimer’s disease in MMSE, LIMM, and Trails A.
SVD predicting neuropsychology
Across all individuals and adjusted for diagnostic
group, greater WMH volume was associated with
greater cognitive decline. A doubling of baseline WMH
was associated with a reduction in change for: MMSE
of 0.06 points/year (95% CI, 0.10, 0.00); LIMM
of 0.09 points/year (95% CI 0.15, 0.04); Trails A
of 0.02 100/seconds per year (95% CI 0.03,
0.01); Trails B of 0.01 100/seconds per year (95%
CI 0.01, 0.00) (Table 3). Presence of one or more
CMB, compared with no CMB, was associated with
greater decline in MMSE by 0.21 points/year (95%
CI 0.50, 0.02) and LIMM by 0.32 points/year
(95% CI 0.55, 0.09) adjusting for WMH and
lacunes, but there was little evidence of associations
with changes in Trails A or Trails B. There was no evi-
dence WMH or CMB had a differential effect by diag-
nostic group on change over time in any of the
neuropsychology outcomes (P> 0.3, all tests). There
was no evidence of an interaction between CMB and
WMH for any neuropsychological test outcome
(P> 0.2, all tests).
Disease-progression measure
modelling
Four hundred and fifty individuals had complete datasets
that were used in the SuStaIn EBM and cross-cluster
group analyses. Figure 3 and Table 4 show four different
groups of individuals identified from this technique, and
Table 5 shows summary statistics for the biomarkers
used in SuStaIn EBM by group.
Group 1 shows a sequence with ptau, tau and the Ab
1–42 as initial events, followed by whole-brain atrophy
rates (BBSI) and LIMM, then MMSE and hippocampal
atrophy rates (HBSI), the Trails tests and finally WMH.
Group 2 has whole-brain atrophy rate (BBSI) as the
first event, followed by hippocampal atrophy rate (HBSI)
and WMH, then LIMM, Ab 1–42, and then MMSE, tau,
ptau and the other psychological measures.
Group 3 has Ab 1–42 as the first event, then WMH,
followed by Trails B then A, then both tau and ptau and
atrophy rate measures (BBSI and HBSI), and finally
LIMM and MMSE.
Group 4 shows LIMM as the first event, then Trails B,
Trails A and MMSE and then all other measures in a
block of uncertain ordering.
In terms of other characteristics, significant differences
across the groups were shown according to proportions
of diagnostic groups, SuStaIn stage, baseline age, gender,
hypertension history, APOEe4 status, change in LIMM,
and presence of at least one CMB (see Table 4). Notable
features of Group 1, the largest group of 223 individuals,
were that this group had the lowest proportion of EMCI,
the highest proportion of the lowest SuStaIn stage cat-
egory and APOE e4 carriers (49%) and the lowest
LIMM improvement scores (0.4 points/year). Group 2
had the highest proportion of men (65%) and a distribu-
tion of proportions of diagnoses similar to Group 1 al-
beit with the highest proportion of SMCs (6%) and the
joint highest proportion of Alzheimer’s disease (12%).
For Group 3, this had the highest proportion of controls
Table 2 Results of the models of brain and hippocampal atrophy rate
a) Whole-brain atrophy rate, ml/year b) Hippocampal atrophy rate, ml/year
Control 5.3 [4.7, 5.9] 0.044 [0.036, 0.053]
SMC 5.3 [4.3, 6.3] 0.039 [0.019, 0.059]
EMCI 6.8** [6.2, 7.4] 0.058* [0.048, 0.069]
LMCI 9.3** [8.0, 10.5] 0.113** [0.094, 0.132]
Alzheimer’s disease 14.7** [12.9, 16.4] 0.185** [0.155, 0.215]
Change in atrophy rate Individual models Adjusted model Individual models Adjusted model
for a doubling of WMH
volume
0.3 (0.01) [0.1, 0.6] 0.3 (0.03) [0.0, 0.6] 0.013 (<0.001) [0.009, 0.017] 0.013 (<0.001) [0.008, 0.017]
for one or more CMBs 1.5 (0.004) [0.5, 2.5] 1.4 (0.007) [0.4, 2.4] 0.029 (0.001) [0.013, 0.045] 0.021 (0.009) [0.005, 0.04]
The top half of the table represents mean [95% CI] atrophy rates in mls per year are shown for the 5 diagnostic groups. The atrophy rates are the mean predicted rate of change
per year in each group calculated from the mixed model. The bottom half of the table shows the individual effects of WMH and CMBs on atrophy rates together with mutually
adjusted associations that are also adjusted for lacunes. Results here are changes in atrophy rate for given increases in SVD, (P-value), [95% CI]. All models are adjusted for total
intracranial volume. Values in the bottom half of the table are adjusted for diagnostic group.
EMCI, Early Mild Cognitive Impairment; LMCI, Late Mild Cognitive Impairment; SMC, Subjective Memory Concern; SVD, small vessel disease; WMH, white matter hyperintensity.
*P-value represents a difference in rates from controls at P< 0.05.
**Significantly different from controls P< 0.01.
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(37%) and EMCI (46%), the lowest proportion of LMCI
(14%) and no Alzheimer’s disease subjects. This group
had the highest proportion of the most severe SuStaIn
stage category (18%). This was the oldest group at
75.8 years with the highest history of hypertension (71%)
and microbleeds (26%) and the lowest BMI. Group 4
was the smallest group (43 individuals) with the highest
proportion of LMCI (42%) and the joint-highest propor-
tion of Alzheimer’s disease (12%), the lowest proportion
of controls (2%) and no SMC and the lowest proportion
of the most severe SuStaIn stage category (5%). This
group had the highest change in LIMM (1.7 points per
year improvement), the lowest proportion of men (44%),
and the highest BMI.
We investigated baseline depression scores over the
four groups and found borderline evidence in differences
across groups with slightly higher mean scores in Group
4 (P¼ 0.06). We also investigated conversion status dur-
ing the 12-month period from baseline. Conversion from
MCI to dementia occurred at rates of 5, 7, 3 and 5%
for Groups, 1, 2, 3 and 4, respectively. From Group 1,
1% converted from normal cognition to MCI and 3%
from Groups 2 and 3. Reversion from MCI to normal
cognition after 12 months occurred at rates of 2, 1, 5
and 7% for Groups 1, 2, 3 and 4, respectively.
Discussion
This study provides evidence that presumed SVD markers
are associated with measures of disease progression. We
found that baseline WMH volume and CMB presence
were independently associated with increased whole-brain
and hippocampal atrophy rate and decline in general cog-
nition and logical memory performance. We established
four distinct groups with different biomarker sequences
with WMH being an early event for two groups and a
later event for two others.
The four groups identified by disease-progression mod-
elling potentially represent different phenotypes in
ADNI2/Go. Group 1 individuals, about half of those ana-
lysed, may be on a typical Alzheimer’s disease pathway
with CSF tau and amyloid measures being the first bio-
markers becoming abnormal. These individuals had an
average CSF amyloid of 247 pg/ml which indicates amyl-
oidosis (the cut-point has been reported as 254 pg/ml)
and the highest tau and ptau levels. In this group, WMH
development was a later event following amyloid and tau
pathology and neurodegeneration. WMH can be caused
by pathologies other than cerebrovascular disease and
WMH here may be the result of neurodegeneration or
classical Alzheimer’s disease pathologies.29,30 Group 2,
with early neurodegenerative markers, could be a ‘sus-
pected non-Alzheimer’s disease pathophysiology’31 or
‘non-Alzheimer’s disease pathological change’ group.5
This group had the highest atrophy rates and relatively
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average. The third and oldest group, which was the least
overweight, showed more mixed pathology with amyloid-
osis and WMH being early events. The average CSF
amyloid level was the lowest of all groups. This group
may represent those with some cerebral amyloid angiop-
athy (CAA) since they had the highest CMB proportion.
The fourth and smallest group, showed early cross-sec-
tional neuropsychological score abnormalities with little
certainty regarding imaging and CSF measure ordering.
This group improved most on logical memory test over
one year but had the lowest baseline scores. These indi-
viduals had the lowest proportion in the most severe
SuStaIn stage category and were most overweight. This
group may represent those who may, on average, have
temporary impairments.
Our findings, from the disease-progression modelling
results in Group 3 in particular, are similar to another
publication which shows vascular dysfunction as an early
disease event.32 Our work differs as we assessed WMH
and CMB as well as progression heterogeneity. Similar
work in a different cohort established four clusters which
approximated to: preclinical typical Alzheimer’s disease;
mixed vascular and preclinical Alzheimer’s disease; atro-
phy-based; typical ageing.33 Other research showed differ-
ent patterns of biomarker evolution in amyloid positive
versus negative individuals from ADNI1.34 This approach
is similar to ours as different patterns of disease progres-
sion are expected. Our work differs by including SVD
markers and allowing groups to be determined by the
data Another study assessed clusters using baseline MRI,
CSF and serum biomarkers in ADNI1 MCI subjects.35
That study found considerable heterogeneity in the MCI
population with four different clusters that approximated
to: controls; Alzheimer’s diseases; and two early
Alzheimer’s disease groups. One of these early
Alzheimer’s disease groups did not seem to conform to
the expected progression models suggesting that not all
individuals are on the same trajectory. Our work extends
this by including all newly enrolled ADNI2/Go subjects
and including presumed cerebrovascular, CSF, atrophy
and cognitive scores.
The atrophy rate results are in keeping with the litera-
ture.36–38 Approximate whole-brain atrophy rates as %
baseline volume per year were controls: 0.5; SMC: 0.5;
EMCI: 0.6; LMCI 0.9; Alzheimer’s disease: 1.4.
Analogous hippocampal rates were controls: 0.7; SMC
0.7; EMCI: 1.1; LMCI 2.2; Alzheimer’s disease: 4.1.
This work confirms that greater WMH volumes are
associated with subsequent brain volume decline, as
shown previously.6–8,39 Converting our reported effects
from ml/year to %/year of baseline volume, a doubling
of WMH was associated with an approximate increase of
0.03%/year for brain atrophy rates, and 0.25%/year for
hippocampal atrophy rates. Others have found that
greater WMH volumes are associated with reductions in
temporal lobe volumes in MCI.40–43 Our work extends
this by reporting that the relationship between WMHs
and progressive atrophy is independent of other markers
of presumed SVD. A novel finding of this study is that
CMB presence is associated with higher brain and hippo-
campal atrophy rates. The effect size was large: presence
of a CMB associated with an increase in atrophy rate
equivalent to approximately 25% of the atrophy rate in
controls without a CMB. Two studies have found associ-
ations between CMBs and cross-sectional measures of
brain atrophy.44,45 One study found no evidence for a re-
lationship between newly developing CMBs and brain
volume change.9 Atrophy rate being related to CMBs
may be driven by underlying advanced Alzheimer’s dis-
ease pathology causing CAA and micro-haemorrhage.
The CMB prevalence in this study was 15%, which is
similar to other comparably aged groups: 11% and
Figure 3 Results from disease progression modelling analyses. Subject numbers for each group are: Group 1 (223); Group 2 (108);
Group 3 (76); Group 4 (43). Only continuous complete-case biomarker variables were used. No time scale is imposed on the event position
(x-axis); events may be close together or distant in time. Positioning for all biomarkers of interest (y-axis) in all groups is presented. Each
entry of each positional variance diagram corresponds to the probability each biomarker (y-axis) will become abnormal at each position in the
sequence (x-axis) estimated by the SuStaIn EBM algorithm, ranging from 0 in white to 1 in black. Definitions: cerebrospinal fluid (CSF);
amyloid beta 1–42 (Ab); total tau (tau); phosphorylated tau 181 (p-tau); brain boundary shift integral atrophy rate over 12 months (BBSI);
hippocampal boundary shift integral atrophy rate over 12 months (HBSI); Mini Mental State Examination (MMSE); logical memory immediate
recall (LIMM).
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31%46,47; although our study had a higher field-strength
scanner compared with these studies (3 T compared with
1.5 T) the latter used a thinner-slice gradient-echo tech-
nique. Furthermore, our study did not include those with
a high vascular disease burden.
Our finding that WMHs are associated with neuro-
psychological decline is in keeping with previous find-
ings48,49 including from this cohort.50 This work extends
the literature by showing the WMH-cognitive decline re-
lationship to be independent of CMBs and lacunes.
Presence of a CMB was also associated with decline in
logical memory which was also independent of lacunes
and WMH. This is broadly in line with results showing
newly developing CMBs are associated with decline.51
However, although a recent review suggested that CMBs
affected global cognitive performance, it concluded that
CMBs mainly affect executive function which we did not
find.49
A strength of this work is that we used multiple meth-
odologies to investigate relationships between SVD and
Alzheimer’s disease biomarkers. However, limitations in-
clude that this dataset was select; ADNI participants are
in relatively good health without severe vascular disease.
We did not look at the effect of number or locations of
CMB, but assumed global effects on outcomes for this
first analysis. Location of SVD is an important topic for
future research since those with lobar CMB may have
different associations with progression measures com-
pared with those with deep/basal ganglia CMBs. Mis-seg-
mentation of WMH does occur with automated
algorithms and semi-automatically, or manually, segment-
ing WMH may reveal different results, however, the algo-
rithm used has shown good comparability compared with
semi-automated (guided-manual) segmentations50 and seg-
mentations were visually inspected. Importantly, follow-
up in the Alzheimer’s disease group was shorter which
limits the extent to which changes can be detected in this
group; caution is needed when interpreting between-group
differences. Furthermore, participants with vascular
lesions in the early stages of disease (controls, SMC,
EMCI), may not be on the same mechanistic pathway to
cognitive decline and dementia as LMCI and Alzheimer’s
Table 4 Analysis of cross-sectional and longitudinal variables of interest that were not entered into the SuStaIn
EBM algorithm according to groups (clusters) derived from the SuStaIn EBM algorithm
Group 1 223 Group 2 108 Group 3 76 Group 4 43 P-value across
groups
Diagnosis % C/SMC/EMCI/LMCI/Alzheimer’s disease 26/3/37/24/10 21/6/44/17/12 37/3/46/14/0 2/0/44/42/12 <0.001
Stage % 0–1/2–3/4–5/6–7/8–10 47/14/10/13/17 36/20/21/10/12 33/32/14/3/18 42/26/26/2/5 <0.001
Age at baseline, years 71.2 (7.0) 72.5 (7.2) 75.8 (6.2) 71.4 (8.5) <0.001
Male % 48 65 54 44 0.018
Education, years 16.2 (2.5) 16.6 (2.8) 16.4 (2.4) 15.6 (2.7) 0.31a
History of hypertension % 44 44 71 44 <0.001
Smoking never/previously/current % 60/39/1 61/32/6 55/43/1 63/35/2 0.13
Body Mass Index, kg/m2 27.3 (4.6) 27.7 (5.0)c 26.8 (5.0) 29.3 (6.5) 0.046
Percentage with diabetes 9 10 7 16 0.38
APOE e4 carrier % 49 34 46 28 0.010
Geriatric depression score (GDS) 1.4 (1.4) 1.3 (1.3) 1.2 (1.5) 1.9 (1.7) 0.06
MMSE (pt/year) 0.4 (2.0) 0.3 (2.1) 0.7 (1.5) 0.2 (1.7) 0.41
Trails A (pt/year) 2.5 (14.4) 2.6 (13.8) 0.1 (12.9) 0.4 (13.0) 0.33
Trails B (pt/year) 10.9 (37.6) 10.9 (49.5) 6.9 (51.9) 1.6 (39.2) 0.34
LIMM (pt/year) 0.4 (3.0) 1.0 (3.0) 0.9 (2.8) 1.7 (3.2) 0.03
Microbleeds % at least 1 11 19 26 7 0.004
Brain volume, ml 1064 (107) 1087 (107) 1072 (96) 1065 (106) 0.44b
Hippocampal volume, ml 5.22 (0.82) 5.36 (0.72) 5.32 (0.66) 5.23 (0.88) 0.27b
EMCI, Early Mild Cognitive Impairment; LIMM, logical memory immediate recall score; LMCI, Late Mild Cognitive Impairment; MMSE, Mini-Mental State Examination; SMC,
Subjective Memory Concern; WMH, white matter hyperintensity.
aAdjusted for gender.
bAdjusted for TIV, age and gender.
cData missing in one individual.
Table 5 Mean (SD) values of variables used in SuStaIn










Ab_1–42, pg/ml 247.0 (83.9) 271.5 (88.8) 182.7 (44.1) 300.7 (65.6)
Total Tau, pg/ml 92.5 (49.9) 65.0 (33.4) 68.7 (32.7) 54.0 (18.9)
Ptau_181, pg/ml 28.7 (13.8) 20.6 (10.6) 25.0 (10.7) 19.1 (6.2)
BBSI, mls/year 6.7 (8.2) 12.5 (5.2) 6.6 (7.1) 4.0 (7.1)
HBSI, mls/year 0.07 (0.11) 0.13 (0.12) 0.06 (0.10) 0.02 (0.10)
log2WMH, ml 11.3 (1.2) 12.5 (1.5) 12.7 (1.4) 11.5 (1.2)
MMSE,/30 27.8 (2.2) 27.7 (2.3) 29.0 (1.0) 27.3 (2.6)
TrailsA,/150 36.1 (16.3) 33.8 (10.2) 41.8 (14.8) 43.5 (19.7)
TrailsB ,/300 94.5 (55.7) 90.6 (39.7) 117.4 (64.2) 120.5 (61.4)
LIMM,/25 10.7 (4.4) 10.1 (4.3) 12.2 (3.5) 7.5 (2.7)
All values are derived from baseline measures apart from the BBSI and HBSI which
was calculated from the baseline and 12-month interval scans.
BBSI, Brain Boundary Shift Integral; HBSI, Hippocampal Boundary Shift Integral; LIMM,
logical memory immediate recall score; MMSE, Mini-Mental State Examination; WMH,
white matter hyperintensity.
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disease groups. A consideration is that we did not adjust
for age when assessing the effects of SVD on neuro-
psychological scores or atrophy rates. We chose this ap-
proach since age and SVD are strongly associated and
age may act as a proxy for the accumulation of vascular
disease and interact with processes along the causal path-
way. We also did not investigate the effects of: education;
APOE e4; disease severity; disease length on outcomes.
We found a very low prevalence of lacunes (2%) and
therefore did not present the lacune effects on outcomes.
This low prevalence may be in part due to the fact that
we only assessed lacunes in the white matter. We did not
have complete data on all subjects to include in the
SuStaIn EBM and this may have influenced the findings
of this approach. We did not transform the neuropsycho-
logical scores used in the SuStaIn EBM models since
there was no adequate transform for MMSE. Further
work using groupings derived from data-driven
approaches will be important. For example, investigating
progression and eventual pathological examination of
brain tissue according to grouping may reveal differences
in outcomes and underlying (co)pathologies. Notably, re-
cent work has suggested that WMHs are not always
associated with vascular disease at post mortem30.
Autopsy confirmation of diagnosis was not available in
this study.
In summary, WMHs and CMBs are independently
associated with brain and hippocampal volume change.
This suggests that CMBs and WMHs have independent
mechanisms which may contribute to neurodegeneration.
WMH may be an early event for groups that either show
suspected non-Alzheimer’s disease pathology, or older
subjects that may have mixed Alzheimer’s and cerebro-
vascular disease or CAA. Markers of presumed SVD are
important to consider when assessing decline in non-de-
mented and clinical Alzheimer’s disease subjects. The het-
erogeneity found in this cohort suggests that different
clinical approaches may be needed for different groups of
individuals.
Supplementary material
Supplementary material is available at Brain
Communications online.
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